Clinical trial · Observational
Fluid Biopsy for the Diagnosis of Lung Cancer
Establishing a Diagnosis of Lung Cancer Through a Fluid Biopsy
NCT04162678CI-TRIAL-00094618terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): insufficient accrual
Summary
Brief summary (as posted)
This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Carcinoma | Lung Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
| Liquid Biopsy | Procedure | — | UNRESOLVED |
| Medical Chart Review | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Diagnostic (blood collection via fluid biopsy, lab analysis)
- description
- Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.
- interventionNames
- Procedure: Biospecimen Collection
- Other: Laboratory Biomarker Analysis
- Procedure: Liquid Biopsy
- Other: Medical Chart Review
Primary outcomes (1)
- measure
- Clinical diagnosis of lung cancer
- timeFrame
- Within 90 days of tissue biopsy
- description
- Descriptive statistics including sensitivity, specificity, positive, and negative predictive value will be tabulated.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Scheduled to undergo a diagnostic biopsy for possible lung cancer or * Completed a diagnostic lung cancer biopsy in the prior 2 weeks and has not yet undergone treatment or * Planning or completed in the last 2 weeks a CT lung cancer screen * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study * Known other solid tumor malignancy other than lung cancer requiring ongoing active treatment
References
Publications (0)
Data not yet available
No reference posted for this study.